Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
BioPharma Credit PLC - life sciences debt investment trust - Notes Monday's announcement from Ipsen regarding its agreement to acquire Epizyme Inc. BioPharma has a $110 million investment in a senior secured loan in Epizyme, which it says would be prepaid upon closing of the acquisition. ‘The loan was made in four different tranches with each tranche having a different prepayment economics. Depending on the actual timing of the prepayment, the company would be expected to receive between $3 million to $7 million in prepayment and make-whole fees,’ company explains.
Current stock price: $0.95
12-month change: down 2.5%
Copyright 2022 Alliance News Limited. All Rights Reserved.